Format

Send to

Choose Destination
N Engl J Med. 2010 Dec 9;363(24):2310-9. doi: 10.1056/NEJMoa1009406. Epub 2010 Nov 16.

Drug-eluting versus bare-metal stents in large coronary arteries.

Collaborators (135)

Pfisterer M, Kaiser C, Pfisterer M, Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Kiowski W, Bonetti P, DeServi S, Kaiser C, Pfisterer M, Buser P, Brunner-La Rocca HP, Handke M, Hunziker P, Osswald S, Jeger R, Sticherling C, Zellweger M, Galatius S, Madsen JK, Abildgaard U, Galloe A, Hansen PR, Jensen JS, Hansen LK, Erne P, Jamshidi P, Auer M, Eberli F, Fischer T, Lindner M, Kurz D, Friedlingsdorf J, Tueller D, Zbinden R, Alber H, Pachinger O, Rickli H, Weilenmann D, Joerg L, Ammann P, Pedrazzini G, Mocetti T, Hornig B, Kohler C, Kiowski W, Ammann W, Bertel O, Straumann E, Bonetti P, Dubach P, Mueller P, De Servi S, Urbano P, Rickenbacher P, Mueller C, Conen D, Brunner-La Rocca HP, Pedersen H, Jazurlo G, Klingenberg M, Harder-Allgöwer A, Bader F, Mueller S, Purschke S, Mueller M, Pedersen M, Ricard I, Brunner-La Rocca HP, Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Ricard I, Brunner-La Rocca H, Buser P, Jeger R, Osswald S, Handke M, Zellweger M, Jensen JS, Abildgaard U, Madsen JK, Galloe A, Hansen PR, Fischer T, Kurz D, Tueller D, Zbinden R, Pachinger O, Weilenmann D, Joerg L, Moccetti T, Kohler C, Naegeli B, Kiowski W, Ammann F, D'Urbano M, Fetiveau R, Rickenbacher P, Conen D, Mueller C, Pedersen H, Jazurlo G, Klingenberg M, Harder-Allgöwer A, Bader F, Mueller S, Purschke S, Mueller K, Pedersen JL, Mehmann B, Frey C, Wanitschek M, Steven G, Rossi M, Pasotti E, Monti C, Petrova I, Stefanin C, Francolino D, Pfisterer M.

Author information

1
Department of Cardiology, University Hospital, CH 4031 Basel, Switzerland. ckaiser@uhbs.ch

Abstract

BACKGROUND:

Recent data have suggested that patients with coronary disease in large arteries are at increased risk for late cardiac events after percutaneous intervention with first-generation drug-eluting stents, as compared with bare-metal stents. We sought to confirm this observation and to assess whether this increase in risk was also seen with second-generation drug-eluting stents.

METHODS:

We randomly assigned 2314 patients needing stents that were 3.0 mm or more in diameter to receive sirolimus-eluting, everolimus-eluting, or bare-metal stents. The primary end point was the composite of death from cardiac causes or nonfatal myocardial infarction at 2 years. Late events (occurring during months 7 to 24) and target-vessel revascularization were the main secondary end points.

RESULTS:

The rates of the primary end point were 2.6% among patients receiving sirolimus-eluting stents, 3.2% among those receiving everolimus-eluting stents, and 4.8% among those receiving bare-metal stents, with no significant differences between patients receiving either drug-eluting stent and those receiving bare-metal stents. There were also no significant between-group differences in the rate of late events or in the rate of death, myocardial infarction, or stent thrombosis. Rates of target-vessel revascularization for reasons unrelated to myocardial infarction were 3.7% among patients receiving sirolimus-eluting stents, 3.1% among those receiving everolimus-eluting stents, and 8.9% among those receiving bare-metal stents. The rate of target-vessel revascularization was significantly reduced among patients receiving either drug-eluting stent, as compared with a bare-metal stent, with no significant difference between the two types of drug-eluting stents.

CONCLUSIONS:

In patients requiring stenting of large coronary arteries, no significant differences were found among sirolimus-eluting, everolimus-eluting, and bare-metal stents with respect to the rate of death or myocardial infarction. With the two drug-eluting stents, similar reductions in rates of target-vessel revascularization were seen. (Funded by the Basel Cardiovascular Research Foundation and the Swiss National Foundation for Research; Current Controlled Trials number, ISRCTN72444640.).

PMID:
21080780
DOI:
10.1056/NEJMoa1009406
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center